Incorrect password
evipedia.ai Suggest Edit

Melatonin for Health & Longevity

Evidence Review created on 04/27/2026 using AI4L / Opus 4.7

Also known as: N-Acetyl-5-Methoxytryptamine, MLT

Motivation

Melatonin (N-Acetyl-5-Methoxytryptamine) is a hormone produced naturally by the pineal gland in response to darkness. Long recognized as the body’s primary signal for sleep, it has become one of the most widely used over-the-counter supplements in the United States, where sales rose sharply in recent years. Its low cost, availability without prescription, and reputation as a sleep aid have made it a default choice for people experiencing insomnia, jet lag, or shift-work disruption.

Beyond regulating the sleep-wake cycle, melatonin acts as a potent antioxidant, free radical scavenger, and immune modulator. Endogenous production declines substantially with age, prompting interest in whether supplementation can support cardiovascular health, inflammatory balance, and cellular resilience over the long term. At the same time, supplement quality varies widely, and recent observational signals around long-term cardiovascular safety have reopened discussion about optimal dose and duration.

This review examines the evidence on melatonin in the context of health optimization and longevity, covering its mechanisms, documented benefits and risks, therapeutic protocols, monitoring approach, and emerging research that may reshape how it is used.

Benefits - Risks - Protocol - Conclusion

Curated resources providing a high-level overview of melatonin in the context of health and longevity.

  • Melatonin for Sleep, Jet Lag, and Beyond - Rhonda Patrick

    Comprehensive topic overview synthesizing melatonin’s role as a chronobiotic, antioxidant, and immune modulator, with discussion of dosing strategies, supplement quality, and mechanisms relevant to longevity.

  • Concerning Findings on Melatonin Content in Over-the-Counter Supplements - Peter Attia

    Examines independent testing showing labeled vs. actual melatonin content varies widely in commercial products, and argues for conservative dosing at 0.3 mg with short-term use.

  • A Case for Higher-Dose Melatonin - William Faloon

    Reviews melatonin’s antioxidant, anti-cancer, immune, and anti-inflammatory actions and the rationale for its use as part of a longevity-oriented supplement strategy, including discussion of higher dose ranges used in research. Note: Faloon co-founded Life Extension Foundation, which sells melatonin supplements; this represents a direct commercial interest in the recommendation.

  • Melatonin as an Anti-Aging Therapy for Age-Related Cardiovascular and Neurodegenerative Diseases - Martín Giménez et al., 2022

    Narrative review covering melatonin’s neuroprotective and cardioprotective properties, mitochondrial function, and rationale for use as an adjunctive longevity intervention.

  • Melatonin and Aging - Bondy, 2023

    Narrative review describing how melatonin’s antioxidant, immune-modulating, and mitochondrial properties may slow several age-related changes, with particular focus on the moderation of immune decline and chronic disease risk in older adults.

No dedicated stand-alone article from Andrew Huberman was found. Huberman discusses melatonin primarily as part of broader sleep-supplement comparisons in podcast episodes, often suggesting alternatives such as magnesium threonate and apigenin for routine sleep support. Chris Kresser has no dedicated article on melatonin; mentions appear only inside broader sleep-hygiene posts.

Grokipedia

Melatonin

Provides a comprehensive overview of melatonin as a neurohormone, covering its biosynthesis from tryptophan, circadian regulation via the suprachiasmatic nucleus, receptor pharmacology, and established clinical uses including sleep disorders and jet lag.

Examine

Melatonin

Offers a regularly updated evidence summary of melatonin supplementation, including dosing recommendations starting from 0.3 mg, effects on sleep onset latency and total sleep time, safety data, and notes on the well-documented quality-control issues with over-the-counter products.

ConsumerLab

Melatonin Supplements Review

Provides independent third-party testing of melatonin supplements, comparing labeled versus actual melatonin content, evaluating product purity, and offering cost comparisons across formulations ranging from 0.3 mg to over 10 mg.

Systematic Reviews

Key systematic reviews and meta-analyses examining melatonin supplementation across sleep, cardiometabolic, and inflammatory outcomes.

Mechanism of Action

Melatonin acts through multiple interconnected pathways relevant to sleep, oxidative stress, immune function, and cellular metabolism.

  • Circadian regulation: Melatonin binds to MT1 and MT2 receptors (melatonin receptor types 1 and 2, G protein–coupled receptors found throughout the body) in the SCN (suprachiasmatic nucleus, the brain’s master circadian clock). MT1 activation promotes sleepiness by reducing neuronal firing, while MT2 activation shifts circadian phase. These receptors signal mainly through Gi proteins, lowering cAMP (cyclic adenosine monophosphate, a second-messenger molecule) and modulating downstream pathways including PKC (protein kinase C) and ERK (extracellular signal-regulated kinase).

  • Antioxidant defense: Melatonin directly scavenges ROS (reactive oxygen species, unstable molecules that damage cells) and RNS (reactive nitrogen species). Its metabolites are themselves antioxidants, producing a cascading effect. It also upregulates endogenous antioxidant enzymes, including SOD, glutathione peroxidase, and catalase.

  • Mitochondrial protection: Melatonin accumulates in mitochondria at concentrations far above plasma levels, where it preserves the electron transport chain, stabilizes membrane potential, and limits oxidative damage. This mitochondrial-targeted action is a central mechanism in proposals that frame melatonin as a longevity-relevant intervention.

  • Immune modulation: At physiological concentrations melatonin enhances innate and adaptive immune responses, including natural killer cell activity and T-helper cell function. At higher pharmacological doses it shows anti-inflammatory effects through suppression of NF-κB (nuclear factor kappa-B, a master regulator of inflammation) signaling and reduced pro-inflammatory cytokine output.

  • Oncostatic properties: Melatonin inhibits tumor growth in laboratory and animal models through anti-angiogenesis (blocking new blood-vessel formation), promotion of apoptosis (programmed cell death), modulation of estrogen receptor activity, and effects on telomerase in some cancer cell lines. Robust human clinical evidence for cancer prevention is lacking.

Key pharmacological properties: Oral immediate-release melatonin has low and variable oral bioavailability (typically ~3–15%), an elimination half-life of approximately 20–50 minutes, and broad tissue distribution including the brain. It is metabolized primarily in the liver by CYP1A2 (cytochrome P450 1A2, a major drug-metabolizing enzyme), with minor contributions from CYP2C19, producing 6-sulfatoxymelatonin as the main urinary metabolite.

Historical Context & Evolution

Melatonin was first isolated from bovine pineal gland tissue in 1958 by Aaron Lerner at Yale University, who named it for its ability to lighten frog skin by aggregating melanin. For decades it was studied primarily as a circadian hormone regulating seasonal and daily biological rhythms. By the 1990s it gained widespread public attention following popular books promoting it as a longevity-extending compound and a sleep aid.

The U.S. Dietary Supplement Health and Education Act of 1994 classified melatonin as a dietary supplement rather than a drug, enabling over-the-counter sales without FDA (Food and Drug Administration) premarket approval. This regulatory status, unusual among developed nations (melatonin requires a prescription in much of Europe, Australia, and Japan), allowed rapid market growth, with U.S. sales rising substantially across the late 2010s and early 2020s.

Research focus has expanded well beyond sleep to cardiovascular protection, metabolic health, neurodegeneration, oncology, and aging biology. Findings from earlier decades on melatonin’s antioxidant and mitochondrial actions have not been overturned; rather, the literature has continued to grow and now includes mixed signals — strong RCT evidence for cardiometabolic and inflammatory improvements alongside emerging observational data raising questions about long-term cardiovascular safety. Interest in dose remains contested: low physiological doses (0.3–1 mg) advanced by researchers such as Richard Wurtman compete in the marketplace with high-dose products (3–10 mg) that dominate retail shelves.

Expected Benefits

High 🟩 🟩 🟩

Reduced Sleep Onset Latency

Melatonin consistently shortens the time required to fall asleep across multiple meta-analyses of RCTs. Effects are largest in individuals with delayed sleep phase disorder or jet lag, and when taken 1–3 hours before intended bedtime. A 2024 dose-response meta-analysis identified peak effects at approximately 4 mg taken 3 hours before bedtime, although physiological doses of 0.3–1 mg also produce meaningful reductions.

Magnitude: Pooled reduction of approximately 7–12 minutes in sleep onset latency; up to 20 minutes in individuals with circadian disruption.

Circadian Rhythm Resynchronization

Melatonin is a well-established chronobiotic, capable of shifting the timing of the body’s internal clock. RCT evidence is robust for jet lag, shift-work adjustment, and delayed sleep–wake phase disorder, with consistent improvements in subjective alertness and sleep timing.

Magnitude: Reduction of jet lag severity by approximately 40–50% in controlled trials; phase-shift effects of 1–2 hours when timing is optimized.

Medium 🟩 🟩

Modest Improvement in Overall Sleep Quality

Meta-analyses show statistically significant improvements in sleep quality on the PSQI, with the largest effects in individuals with respiratory disease, metabolic disorders, or primary sleep disorders. Clinical significance in healthy adults is more modest and debated.

Magnitude: Weighted mean difference of approximately −1.24 points on the PSQI in pooled analyses (clinically meaningful threshold typically 1.5–3 points).

Reduced Inflammatory Markers

A 2025 meta-analysis of 63 RCTs reported significant reductions in CRP, TNF-α, and IL-6 with melatonin supplementation. Effects are most consistent in populations with elevated baseline inflammation, particularly those with diabetes or metabolic syndrome.

Magnitude: CRP reduced by approximately 0.59 mg/L; TNF-α reduced by approximately 1.61 pg/mL; IL-6 reduced by approximately 6.43 pg/mL in pooled analyses.

Enhanced Antioxidant Capacity

Supplementation consistently increases total antioxidant capacity and upregulates endogenous antioxidant enzymes including glutathione and SOD, with the most consistent signals in metabolically compromised populations.

Magnitude: Total antioxidant capacity increased by approximately 0.15 mmol/L; SOD activity significantly elevated across multiple RCTs.

Improved Cardiometabolic Markers

Pooled data from 63 RCTs indicate that melatonin reduces systolic blood pressure, fasting blood glucose, LDL cholesterol, and total cholesterol while modestly increasing HDL cholesterol. Effects are typically small but statistically significant.

Magnitude: Systolic blood pressure reduced by approximately 2.34 mmHg; fasting blood glucose reduced by approximately 11.63 mg/dL; LDL cholesterol reduced by approximately 6.28 mg/dL.

Low 🟩

Neuroprotective Effects

Animal studies and mechanistic research support melatonin’s neuroprotective potential through mitochondrial protection, antioxidant defense, and anti-inflammatory activity. Human clinical evidence remains limited, with small trials and observational data suggesting potential benefit in neurodegenerative conditions.

Magnitude: Not quantified in available studies.

Oncostatic Activity

Laboratory and animal studies demonstrate anti-cancer effects via inhibition of angiogenesis, promotion of apoptosis, and modulation of estrogen receptor activity. A meta-analysis of cancer-related fatigue found modest benefits with adjunctive melatonin. Large-scale human RCTs for cancer prevention are absent.

Magnitude: Not quantified in available studies.

Speculative 🟨

Longevity Extension

Melatonin’s mitochondrial-protective, antioxidant, and anti-inflammatory profile has led researchers to propose it as a potential longevity-relevant compound. Animal studies in rodents and invertebrates show lifespan extension under melatonin administration. Endogenous melatonin production declines significantly with age, prompting the hypothesis that supplementation may counteract certain aspects of biological aging. Direct human longevity data are absent, and a large planned trial (NCT04631341, targeting elderly participants) has not yet begun recruiting at the time of this review.

Benefit-Modifying Factors

  • Age: Endogenous melatonin production declines substantially with age, with older adults often producing a fraction of the levels seen in younger individuals. Supplementation may therefore have a larger relative effect in older populations, though sleep-specific RCT benefits are stronger in children, adolescents, and individuals with circadian disruption than in older adults with non-comorbid chronic insomnia.

  • Baseline melatonin levels: Individuals with already-suppressed endogenous production (shift work, excessive evening light exposure, age-related decline) are more likely to experience benefit. Those with normal endogenous output may see smaller effects.

  • Genetic polymorphisms: Variants in CYP1A2 (cytochrome P450 1A2, the primary liver enzyme that metabolizes melatonin) create marked between-person differences in melatonin clearance. Slow metabolizers (e.g., carriers of CYP1A2*1C or *1K alleles) may experience prolonged effects and require lower doses. Variants in MTNR1B (melatonin receptor 1B gene) are associated with impaired glucose homeostasis and may modify the metabolic response to supplementation.

  • Sex-based differences: Women typically have higher endogenous melatonin levels than men, and some evidence suggests greater sensitivity to exogenous melatonin. Melatonin interacts with reproductive hormone pathways; women of reproductive age should consider potential effects on cycle timing.

  • Pre-existing conditions: Individuals with metabolic disorders, respiratory disease, or circadian disruption tend to show larger sleep quality improvements. Those with autoimmune conditions may be affected by melatonin’s immune-stimulating properties.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Daytime Drowsiness and Impaired Alertness

The most commonly reported side effect across clinical trials and real-world use. Drowsiness can persist into the morning, particularly with higher doses or extended-release formulations, and can impair driving and operation of machinery for several hours post-dose.

Magnitude: Reported in approximately 10–20% of users in clinical trials; dose-dependent.

Supplement Quality and Labeling Inaccuracy

A well-documented problem with the over-the-counter melatonin market. Independent testing has found that a majority of products contain melatonin levels substantially different from what is labeled, with deviations ranging from 83% less to several hundred percent more than claimed. Some products have also been found to contain unlabeled serotonin.

Magnitude: 71–88% of tested products have been inaccurately labeled across multiple independent analyses.

Medium 🟥 🟥

Headache, Nausea, and Dizziness

Common side effects in clinical trials, typically mild and self-limiting. Headache and nausea tend to occur more frequently at doses above 3 mg.

Magnitude: Headache reported in approximately 5–10% of users; nausea in 3–8%; dizziness in 2–5% across clinical trials.

Vivid Dreams and Nightmares

Melatonin can alter dream content, producing unusually vivid or disturbing dreams. Reported across dose ranges but more common at higher doses.

Magnitude: Reported in approximately 5–10% of users; dose-dependent.

Potential Disruption of Endogenous Production

Short-term use does not appear to suppress natural melatonin production in most studies, but the long-term effects of chronic exogenous supplementation on the pineal gland’s endogenous rhythm remain incompletely characterized. Some experts caution that prolonged high-dose use could theoretically downregulate natural production.

Magnitude: Not quantified in available studies.

Low 🟥

Possible Cardiovascular Risk with Long-Term Use ⚠️ Conflicted

A 2025 observational study presented at the American Heart Association Scientific Sessions reported that long-term melatonin use (over one year) in 65,414 adults with insomnia was associated with higher rates of heart failure diagnosis (HR (hazard ratio, a measure of relative risk over time) 1.89), heart failure hospitalization (HR 3.44), and all-cause mortality (HR 2.09) compared with matched controls. The study was a conference abstract, was not peer-reviewed at presentation, cannot establish causation, and may reflect confounding by indication (insomnia itself is associated with cardiovascular risk). Industry and academic commentators noted significant methodological limitations. This signal conflicts with meta-analytic data showing improvement of cardiometabolic markers with melatonin.

Magnitude: HR ~1.89 for heart failure and ~2.09 for all-cause mortality in the observational study; conflicting with RCT-level evidence showing improved cardiometabolic markers.

Hormonal Effects

Melatonin interacts with the HPG axis (hypothalamic–pituitary–gonadal axis, the hormonal signaling pathway connecting the brain and reproductive organs). High-dose or chronic use may affect reproductive hormones; concerns are greatest for children (potential effects on pubertal timing) and women of reproductive age.

Magnitude: Not quantified in available studies.

Speculative 🟨

Interference with Glucose Regulation in Susceptible Individuals

Carriers of the MTNR1B rs10830963 risk allele may experience impaired insulin secretion in response to melatonin. Late-evening melatonin combined with food intake may worsen glucose tolerance in these individuals. The clinical significance of this interaction at typical bedtime supplementation remains unclear.

Risk-Modifying Factors

  • Genetic polymorphisms: CYP1A2 slow metabolizers may experience exaggerated effects and longer duration of action, increasing daytime drowsiness risk. MTNR1B variants (particularly rs10830963) may increase susceptibility to glucose dysregulation.

  • Baseline biomarker levels: Individuals with already low endogenous melatonin (measurable via urinary 6-sulfatoxymelatonin) face lower risk of physiological oversupplementation, while those with normal production may be more susceptible to supraphysiological effects. Elevated baseline inflammatory markers (CRP, IL-6) or impaired fasting glucose may amplify metabolic interactions.

  • Sex-based differences: Women appear more sensitive to exogenous melatonin. Effects on reproductive hormones warrant particular consideration in women of reproductive age and those undergoing fertility treatment.

  • Pre-existing conditions: Individuals with established cardiovascular disease should exercise caution given the emerging observational data. Those with autoimmune conditions may experience disease activity due to melatonin’s immune-stimulating effects. Individuals with depression should be monitored, as melatonin may worsen mood symptoms in some cases.

  • Age-related considerations: Older adults metabolize melatonin more slowly and typically tolerate lower doses better. Children are at risk for accidental overdose from high-dose gummies, with thousands of pediatric emergency department visits reported in recent years for unsupervised melatonin ingestion.

Key Interactions & Contraindications

  • Sedative medications: Benzodiazepines (alprazolam, diazepam, lorazepam), Z-drugs (zolpidem, zaleplon, eszopiclone), and sedating antidepressants (trazodone, amitriptyline, mirtazapine) combined with melatonin produce additive sedation. Severity: caution; clinical consequence: excessive sedation, impaired alertness, increased fall risk. Mitigation: avoid concurrent dosing or reduce melatonin to the lowest effective dose; do not drive or operate machinery within 4–5 hours.

  • Over-the-counter sedatives: OTC (over-the-counter) sleep aids containing diphenhydramine (Benadryl, ZzzQuil) or doxylamine (Unisom) produce additive sedation. Severity: caution; clinical consequence: excessive next-day drowsiness and falls, particularly in older adults. Mitigation: avoid combination, especially in adults over 65.

  • Anticoagulants and antiplatelet agents: Warfarin, direct oral anticoagulants (apixaban, rivaroxaban), and antiplatelet drugs (clopidogrel, aspirin) may have increased bleeding risk when combined with melatonin. Severity: caution; clinical consequence: increased bleeding risk. Mitigation: monitor INR (international normalized ratio, a measure of blood-clotting time) for warfarin users; report any unusual bruising or bleeding.

  • Immunosuppressants: Cyclosporine, tacrolimus, sirolimus, and corticosteroids may have reduced effectiveness due to melatonin’s immune-stimulating effects. Severity: absolute contraindication in transplant recipients; clinical consequence: potential rejection or loss of therapeutic effect. Mitigation: avoid melatonin in transplant patients and those on chronic immunosuppression.

  • Antihypertensive medications: ACE inhibitors (angiotensin-converting enzyme inhibitors; lisinopril, enalapril), ARBs (angiotensin receptor blockers; losartan, valsartan), calcium channel blockers (amlodipine, diltiazem), and beta-blockers (metoprolol, atenolol) — RCT data show melatonin lowers blood pressure independently, but case reports describe blood pressure elevations in some users on antihypertensives. Severity: monitor; clinical consequence: unpredictable blood pressure changes. Mitigation: monitor home blood pressure for the first 2–4 weeks after starting.

  • Antidiabetic medications: Insulin, sulfonylureas (glimepiride, glipizide), metformin, and SGLT2 (sodium-glucose cotransporter 2) inhibitors (empagliflozin, dapagliflozin) — melatonin can affect glucose metabolism, particularly in MTNR1B variant carriers. Severity: monitor; clinical consequence: altered glycemic control. Mitigation: increase home glucose monitoring during the first 4–8 weeks; avoid bedtime carbohydrate-rich meals.

  • CYP1A2 inhibitors: Fluvoxamine, ciprofloxacin, and high-dose caffeine inhibit CYP1A2, the enzyme that metabolizes melatonin. Severity: caution; clinical consequence: elevated melatonin plasma levels and prolonged effect. Mitigation: with fluvoxamine, avoid melatonin or use substantially reduced doses; with ciprofloxacin, separate dosing as feasible and reduce dose; limit late-day caffeine.

  • Supplements with additive sedative or hypnotic effects: Valerian, kava, magnesium, L-Theanine, GABA (gamma-aminobutyric acid, the brain’s primary inhibitory neurotransmitter), glycine, ashwagandha, passionflower, and CBD (cannabidiol) — additive sedation is plausible. Severity: caution; clinical consequence: excessive sedation. Mitigation: avoid stacking multiple sedating supplements at full doses; introduce one at a time.

  • Populations who should avoid melatonin: Pregnant or nursing women (insufficient safety data); transplant recipients and others on chronic immunosuppressive therapy; individuals with active autoimmune disease (e.g., lupus, multiple sclerosis, rheumatoid arthritis on flare); children under 5 (high accidental-overdose risk and limited long-term safety data); individuals with documented severe liver impairment (Child-Pugh Class C) given hepatic metabolism; and individuals with bleeding disorders or those scheduled for surgery within 2 weeks (caution).

Risk Mitigation Strategies

  • Start at the lowest effective dose: Begin at 0.3–0.5 mg taken 1–3 hours before bedtime to mitigate daytime drowsiness, vivid dreams, and supraphysiological effects. Increase only if clearly needed.

  • Choose third-party-tested products: Select brands verified by independent testing organizations such as ConsumerLab, USP (United States Pharmacopeia), or NSF International to mitigate the dosing inaccuracy that affects 71–88% of commercial melatonin products.

  • Use short-term or intermittent protocols: Limit continuous use to 1–2 months and reassess, mitigating the uncertainty around long-term cardiovascular safety raised by the 2025 observational data. Reserve nightly use for clear circadian indications (jet lag, shift work).

  • Time administration appropriately: Take melatonin 1–3 hours before intended sleep, not at the moment of getting into bed, to maximize circadian effect and reduce next-morning grogginess. Avoid driving or operating heavy machinery for 4–5 hours after the dose.

  • Avoid late-evening carbohydrate-rich meals when supplementing: Mitigates potential glucose dysregulation in MTNR1B variant carriers. Allow at least 2 hours between dinner and bedtime melatonin.

  • Disclose use to all healthcare providers: Mitigates interaction risk with anticoagulants, immunosuppressants, antihypertensives, antidiabetic medications, and CYP1A2 inhibitors.

  • Store in childproof containers and keep out of reach of children: Mitigates risk of accidental pediatric ingestion, which has been a significant source of poison-control calls and emergency department visits.

  • Discontinue and reassess if mood, cardiovascular, or autoimmune symptoms emerge: Mitigates risk of mood worsening, hormonal effects, and possible immune-related disease flares.

Therapeutic Protocol

The standard approach reflects consensus from RCTs, dose-response meta-analyses, and expert guidance from leading clinicians.

  • For sleep onset and general sleep support: 0.3–1 mg immediate-release melatonin, taken 1–3 hours before desired bedtime. The 2024 Cruz-Sanabria dose-response meta-analysis identified peak efficacy at approximately 4 mg taken 3 hours before bedtime, but several leading practitioners (including Peter Attia and Andrew Huberman) recommend starting at 0.3 mg, as physiological doses often match or exceed higher doses for sleep with fewer side effects. MIT (Massachusetts Institute of Technology) researcher Richard Wurtman, who held the original patent on low-dose melatonin for sleep, recommended 0.3 mg as a target dose.

  • For sleep maintenance: Consider extended-release formulations or a combination of immediate-release plus extended-release. Several manufacturers offer dual-release products designed to address both sleep onset and middle-of-the-night waking.

  • For jet lag: 0.5–5 mg taken at the destination’s local bedtime, beginning on the day of arrival and continuing for 2–5 days. Higher end of the range may be used for eastward travel across multiple time zones.

  • For shift work: 0.3–3 mg taken before the intended sleep period during the day, combined with daylight-blocking measures (blackout curtains, eye masks).

  • Best time of day: Evening administration only; daytime dosing can disrupt circadian signaling. Optimal timing is 1–3 hours before intended sleep onset, not at the moment of getting into bed.

  • Half-life: Immediate-release melatonin has an elimination half-life of approximately 20–50 minutes (commonly around 40–45 minutes), with elevated blood concentrations persisting for roughly 4–5 hours. Extended-release formulations prolong this window.

  • Single vs. split dosing: A single dose is typical for sleep applications. Combination immediate-release plus extended-release formulations effectively split the pharmacokinetic profile rather than requiring two separate administrations.

  • Genetic considerations: CYP1A2 slow metabolizers may need lower doses due to prolonged clearance. Carriers of MTNR1B risk variants should avoid taking melatonin close to meals because of potential glucose dysregulation. Pharmacogenomic testing can identify the most relevant CYP1A2 variants when justified.

  • Sex-based differences: Women may respond to lower doses than men. Women of reproductive age should consider potential interactions with cycle timing and reproductive hormones. Use in assisted reproduction protocols should occur only under specialist supervision.

  • Age-related considerations: Older adults typically benefit from lower doses (0.3–1 mg) due to slower metabolism and greater sensitivity. Endogenous production declines significantly with age, making supplementation potentially more impactful. Children should only use melatonin under pediatric supervision, starting at the lowest available dose (0.3–0.5 mg) for clear medical indications.

  • Baseline biomarker levels: Individuals with documented low melatonin levels (via urinary 6-sulfatoxymelatonin) are the strongest candidates for supplementation. Those with normal endogenous production may find behavioral interventions (morning bright light exposure, evening light avoidance) more effective.

  • Pre-existing health conditions: Individuals with insomnia comorbid with metabolic or respiratory disease appear to benefit most. Those with autoimmune conditions or on chronic immunosuppressive therapy should avoid melatonin. Anyone with established cardiovascular disease should discuss long-term use with their physician given the emerging observational signals.

Discontinuation & Cycling

  • Duration of use: Melatonin is generally considered safe for short-term use (1–2 months). For jet lag and acute circadian disruption, use is limited to the duration of need (typically 2–7 days). Long-term continuous use beyond 12 months lacks robust safety data, and emerging observational evidence has raised cardiovascular questions that prospective trials have not yet resolved.

  • Withdrawal effects: Melatonin is not considered addictive and does not produce the withdrawal syndrome associated with sedative–hypnotics. Some users report transient difficulty falling asleep (rebound insomnia) for several days after stopping, particularly after prolonged high-dose use, which likely reflects a return to baseline circadian signaling rather than dependence.

  • Tapering: Abrupt discontinuation is generally well tolerated. For users on high doses (3 mg or more) for extended periods, a gradual taper over 1–2 weeks (halving the dose at each step) may smooth the transition.

  • Cycling: Periodic breaks from melatonin (for example, 2–4 weeks off after each 1–2 month course) are commonly suggested by integrative practitioners to prevent potential desensitization and to reassess whether continued supplementation provides incremental benefit. This approach also supports awareness of baseline sleep quality without the supplement.

Sourcing and Quality

  • Third-party testing is essential: Given that 71–88% of tested melatonin supplements are inaccurately labeled, products certified by ConsumerLab, USP (United States Pharmacopeia), or NSF International are particularly important.

  • Formulation selection: Immediate-release tablets and capsules are appropriate for sleep onset difficulties. Extended-release or dual-release formulations address sleep maintenance. Sublingual formulations offer faster absorption. Gummies are popular but have shown the highest rates of dosing inaccuracy and are often best avoided where precision matters.

  • Preferred forms: Synthetic melatonin is preferred over animal-derived (bovine pineal) sources because of purity and consistency concerns. Phytomelatonin (plant-derived) options exist but are less studied.

  • Reputable brands: ConsumerLab and similar testing programs have identified compliant products across multiple brands. Life Extension, NOW Foods, Pure Encapsulations, and Thorne are among the brands that have repeatedly passed independent testing for melatonin content accuracy in low-dose formulations. Low-dose 0.3 mg products are specifically designed to approximate physiological levels.

  • Storage: Store in a cool, dark location; heat and light degrade the compound. Keep out of reach of children due to the high frequency of accidental pediatric ingestion.

Practical Considerations

  • Time to effect: Sleep onset effects typically begin within 30–60 minutes for immediate-release formulations. Circadian phase-shifting effects (for jet lag or shift work) usually require 2–4 days of consistent dosing at the appropriate time. Anti-inflammatory and cardiometabolic benefits seen in RCTs generally emerge after 4–12 weeks of supplementation.

  • Common pitfalls:
    • Taking too high a dose. Many over-the-counter products contain 3–10 mg, well above the physiological range of 0.3–1 mg. Higher doses do not necessarily improve sleep and can increase side effects.
    • Taking melatonin too late. Immediate pre-bedtime dosing is less effective than dosing 1–3 hours before intended sleep, as identified by recent dose-response meta-analyses.
    • Relying on melatonin without addressing sleep hygiene fundamentals. Light exposure management, consistent sleep timing, and bedroom temperature optimization are foundational and should not be replaced by supplementation.
    • Using melatonin gummies, which have the highest documented rates of dosing inaccuracy.

  • Regulatory status: In the United States, melatonin is classified as a dietary supplement under DSHEA (Dietary Supplement Health and Education Act of 1994), meaning it does not require FDA premarket approval and is not subject to pharmaceutical-grade manufacturing standards. In the European Union (most member states), the United Kingdom, Australia, and Japan, melatonin is a prescription medication or controlled substance. This regulatory discrepancy contributes to the quality-control challenges seen in the U.S. market.

  • Cost and accessibility: Melatonin is inexpensive and widely accessible in the U.S. and Canada. Per-dose cost ranges from approximately $0.01 to $0.60 depending on brand, dose, and formulation. It is available without a prescription in these markets.

Interaction with Foundational Habits

  • Sleep: Direct and potentiating. Melatonin acts on the same circadian pathway that proper sleep hygiene targets. Morning bright-light exposure and evening light avoidance amplify the benefit of supplementation; evening blue-light exposure suppresses endogenous melatonin and partly negates dosing. Combining melatonin with consistent sleep timing produces larger and more durable improvements than either alone.

  • Nutrition: Indirect, with potential blunting in genetically susceptible individuals. Late-evening eating, particularly carbohydrate-rich meals, can impair the glucose response in MTNR1B risk-allele carriers when melatonin levels are elevated. Practical implication: take melatonin on a relatively empty stomach and finish dinner at least 2 hours before dosing. Tryptophan-rich foods (turkey, eggs, nuts) support endogenous melatonin synthesis but do not need to be timed to the dose.

  • Exercise: Indirect. Moderate regular exercise supports natural melatonin secretion and circadian stability. Intense late-evening exercise can transiently suppress melatonin release through elevated core body temperature and cortisol; morning or afternoon training is preferable. There is no evidence that melatonin blunts exercise-induced adaptations such as hypertrophy or endurance gains.

  • Stress management: Indirect and potentiating. Chronic stress elevates evening cortisol, which opposes melatonin’s actions and impairs sleep onset. Practices such as meditation, slow breathing, and yoga support the evening cortisol decline that allows robust melatonin release. Melatonin does not directly lower cortisol but can support recovery indirectly through improved sleep quality.

Monitoring Protocol & Defining Success

Baseline labs and tests: Before starting melatonin, especially for goals beyond short-term sleep support, the following assessments establish a starting point and allow tracking of cardiometabolic, inflammatory, and hormonal effects.

Ongoing monitoring: Re-test relevant markers at 8–12 weeks after initiation, then every 6–12 months during continued use; reassess sooner if symptoms or new conditions emerge.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Urinary 6-sulfatoxymelatonin 10–60 mcg per overnight collection Confirms baseline melatonin status First-morning void or overnight collection; establishes whether supplementation is indicated
hs-CRP < 1.0 mg/L Tracks anti-inflammatory effects hs-CRP = high-sensitivity C-reactive protein; conventional range < 3.0 mg/L; fasting sample preferred; avoid testing during acute illness
Fasting glucose 72–85 mg/dL Monitors metabolic effects Conventional range 70–99 mg/dL; particularly relevant for MTNR1B variant carriers; 8–12 hour fast required
HbA1c 4.8–5.2% Tracks long-term glucose trends HbA1c = glycated hemoglobin, a marker of 3-month average blood sugar; conventional range < 5.7%; especially important at higher doses
Lipid panel (total cholesterol, LDL, HDL, triglycerides) LDL < 100 mg/dL; HDL > 60 mg/dL; triglycerides < 100 mg/dL Tracks cardiometabolic effects 9–12 hour fast; track LDL and HDL trends over months
Blood pressure Systolic < 120 mmHg; Diastolic < 80 mmHg Monitors cardiovascular effects Measure at consistent time of day; melatonin can lower systolic BP by ~2 mmHg in pooled data
TSH 1.0–2.5 mIU/L Screens for thyroid interaction TSH = thyroid-stimulating hormone; conventional range 0.4–4.0 mIU/L; melatonin may influence thyroid signaling in some individuals
Liver enzymes (ALT, AST) ALT < 25 U/L (women), < 30 U/L (men); AST similar Monitors hepatic safety ALT = alanine aminotransferase; AST = aspartate aminotransferase; conventional ALT range up to 35–56 U/L; melatonin is hepatically metabolized via CYP1A2

Qualitative markers:

  • Sleep onset time and total sleep time
  • Subjective sleep quality and morning alertness
  • Number and duration of nighttime awakenings
  • Daytime energy and cognitive clarity
  • Mood stability
  • Dream intensity and content

A sleep diary maintained for 2 weeks before starting and for the first 4–8 weeks after initiation provides the most useful subjective baseline.

Emerging Research

  • Cardiovascular safety of long-term use: A large observational study presented at American Heart Association Scientific Sessions 2025 reported associations between long-term melatonin use and increased heart failure and all-cause mortality in adults with insomnia. A planned trial, Melatonin and Risk of Cardiovascular Events and Malignant Tumors in the Elderly (NCT04631341), aims to enroll 10,000 elderly participants to prospectively assess these outcomes; recruitment status remains unconfirmed and results could fundamentally reshape recommendations.

  • Long COVID and sleep disturbance: The RECOVER-SLEEP Appendix_B trial (NCT06404112) is a Phase 2 platform trial evaluating melatonin and tailored lighting for circadian rhythm and sleep disturbance in Long COVID, with approximately 470 participants enrolled. Results may extend melatonin’s clinical applications in post-viral syndromes.

  • Kidney protection: An ongoing trial, Melatonin for Prevention of Antibiotic-Associated Acute Kidney Injury (NCT05084196), is a Phase 3 study enrolling approximately 300 participants to assess whether melatonin can prevent acute kidney injury in hospitalized patients receiving vancomycin and piperacillin-tazobactam, leveraging its antioxidant properties.

  • Pediatric perioperative use: The MELA-PAED trial (NCT05541276) is a Phase 3 randomized, double-blind, placebo-controlled trial evaluating intravenous melatonin for prevention of postoperative agitation and emergence delirium in children, with approximately 400 participants planned.

  • High-dose melatonin in oncology: Preliminary work and expert commentary, including from melatonin researcher Russel Reiter, have proposed that high-dose melatonin (in the 20–100 mg range) may have therapeutic value as an adjunct in cancer care. A meta-analysis on cancer-related fatigue (Li et al., 2025) reported modest benefits, but Phase 3 outcome data for anti-cancer effects remain absent.

  • Melatonin and the gut microbiome: Preclinical evidence suggests melatonin modulates gut microbiome composition and intestinal barrier integrity (Iesanu et al., 2022), opening a new line of research that may connect melatonin to immune function and metabolic health through the gut–brain axis. Human translation remains early.

Conclusion

Melatonin is a well-studied hormone-supplement with strong evidence for shortening sleep onset and resynchronizing the body’s internal clock, particularly in jet lag, shift work, and circadian phase disorders. Pooled clinical-trial data also support meaningful improvements in inflammatory and cardiometabolic markers, with the largest effects in people who already have metabolic or inflammatory burden. Its low cost, broad availability, and favorable short-term safety profile have made it one of the most accessible options in the longevity-oriented toolkit.

Several caveats temper enthusiasm. The over-the-counter market suffers from widespread labeling inaccuracy, making third-party-tested products effectively mandatory rather than optional. Long-term safety beyond a year is not firmly established, with a recent observational signal raising questions about cardiovascular outcomes that prospective trials have not yet resolved. Sleep benefits in healthy adults with non-comorbid insomnia are more modest than the supplement’s reputation suggests, and lower physiological doses taken well before bedtime appear at least as effective as the much higher doses dominating retail shelves.

Overall, the evidence base shows a meaningful short-term sleep and circadian effect, supportive metabolic and inflammatory signals, important quality-control concerns in the supplement market, and an unresolved question around long-term cardiovascular outcomes. A separate caveat applies to advocacy from organizations that market melatonin products, where commercial interests run alongside the recommendations made.

Top - Benefits - Risks - Protocol